Back to all Curatis Holding AG press releases
Curatis Holding AG
- SIX:CURN
Curatis reports 51% first-half revenue increase and progress on corticorelin programme
Published
At a glance
- Company
- Curatis Holding AG
- Listings
- SIX:CURN
- Announcement type
- Financial results
- Published
- Reporting period
- first half of 2026
- Source announcement
- eqs-news.com
| Measure | Figure | Period | Compared with |
|---|---|---|---|
| Net sales from goods and services | CHF 7.9m | first half of 2026 | CHF 5.2m in H1 2025 (up 51%) |
| Loss for the period | CHF -0.4m | first half of 2026 | CHF -1.2m in H1 2025 |
| Cash and cash equivalents | CHF 3.6m | first half of 2026 | CHF 1.9m in 31 December 2025 |
| Net sales from goods | CHF 7.4m | first half of 2026 | CHF 5.0m in H1 2025 (increased by 46%) |
| Net sales from services | CHF 0.6m | first half of 2026 | CHF 0.2m in H1 2025 |
| Gross contribution from goods and services | CHF 1.8m | first half of 2026 | CHF 1.3m in H1 2025 (rose by 32%) |
Figures are quoted from this announcement and selected automatically.
FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices
Announcement Summary
Curatis Holding AG (SIX:CURN, “Curatis”; CURN.SW) reports first-half results, including CHF 7.9m net sales and a CHF -0.4m loss for the period.
- Net sales from goods and services were CHF 7.9m in H1 2026 (H1 2025: CHF 5.2m); loss was CHF -0.4m (H1 2025: CHF -1.2m).
- Cash and cash equivalents were CHF 3.6m (31 December 2025: CHF 1.9m), reflecting a CHF 3.0 million convertible instrument placed in May 2026.
- In March, Curatis signed an exclusive Japan licence with Neupharma, valued at up to CHF 83.5m in payments plus royalties of up to 20%.
- Neupharma met Japan’s health authority, PMDA, to discuss possible development pathways for corticorelin in that market.
- Corticorelin is investigational and not approved for therapeutic use in the United States or elsewhere; assay validation is on track for year-end.
- Curatis confirms projected 2026 revenues of approximately CHF 15m and plans to meet the FDA in the first quarter of 2027.
The company expects during 2027 to complete production of clinical study material and prepare with a contract research organization, including selection of study centers. Its objective remains a break-even result in 2026.
Investor FAQs
Curatis Holding AG reported its first-half 2026 financial results and progress with its corticorelin (C-PTBE-01) programme. The company reported net sales from goods and services of CHF 7.9m, a loss for the period of CHF -0.4m and cash and cash equivalents of CHF 3.6m.
Curatis Holding AG reported net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% from CHF 5.2m in the first half of 2025. Net sales from goods increased by 46% to CHF 7.4m, while net sales from services rose to CHF 0.6m from CHF 0.2m.
Curatis Holding AG said growth was driven by products marketed for some time and by products added to its distribution portfolio in 2025 and 2026. Net sales from both goods and services increased during the period.
Yes, Curatis Holding AG reported a loss for the period of CHF -0.4m, compared with CHF -1.2m in the first half of 2025. The operating result was CHF -401 thousand, compared with CHF -1'291 thousand in the prior-year period.
Curatis Holding AG’s gross contribution from goods and services rose by 32% to CHF 1.8m from CHF 1.3m. The company said its combined cost base grew by 9%, with personnel expenses rising 5% to CHF 1.3m and other operating expenses increasing 17% to CHF 0.6m.
Curatis Holding AG reported cash and cash equivalents of CHF 3.6m at 30 June 2026, compared with CHF 1.9m at 31 December 2025. The company attributed the increase to a CHF 3.0 million convertible instrument placed with a strategic Swiss investor in May 2026 and converted into equity during the reporting period, while cash flow from operating activities was CHF -0.9m and investing activities were CHF -0.4m.
Curatis Holding AG placed a CHF 3.0 million convertible instrument with a strategic Swiss investor in May 2026, which was converted into equity during the reporting period. The company reported net cash inflow from financing of CHF 3.0m.
Curatis Holding AG said it advanced the corticorelin programme through an exclusive Japan licence agreement with Neupharma and continued manufacturing work. It also reported API batches at a higher yield than expected, technical development of the drug product on schedule and a cell-based potency assay on track for validation by year-end.
Curatis Holding AG signed an exclusive licence agreement for corticorelin in Japan with Neupharma in March. The agreement is valued at up to CHF 83.5m in upfront and milestone payments, plus royalties of up to 20%; Curatis said Neupharma met Japan’s health authority, PMDA, to discuss possible development pathways.
Curatis Holding AG is developing corticorelin, also known as C-PTBE-01, to treat peritumoral brain edema. The company describes corticorelin as an investigational drug that is not yet approved for therapeutic use in the United States or elsewhere.
Curatis Holding AG confirmed its full-year guidance of projected revenues of approximately CHF 15m for 2026, compared with CHF 10.8m in 2025, resulting in revenue growth of approximately 40% in 2026. The company’s objective remains a break-even result in 2026.
Curatis Holding AG plans to meet the FDA in the first quarter of 2027 to finalise the pivotal Phase 3 study design for corticorelin. During 2027, the company expects to complete production of clinical study material and prepare for the study with a contract research organisation, including selection of study centres.
Curatis Holding AG is publicly listed on SIX under the ticker shown in the announcement as SIX:CURN. The company also identifies its listed share symbol as CURN.SW.
Curatis Holding AG specialises in the late-stage development and commercialisation of drugs for rare diseases and specialty care. The company said it has a sales portfolio of 50 products and a pipeline of orphan and specialty drugs.
Source announcement
- Company
- Curatis Holding AG
- Title
- Strongest half-year in Curatis’s history — revenue up 51% and significant progress on corticorelin (C-PTBE-01)
- Published
- Source site
- eqs-news.com
Read the source announcement on eqs-news.com
FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.
Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.
Read the original press release
Full text as published, unedited.
Loading the original release…